Loading…

Improving the Enantioselectivity of CHMOBrevi1 for Asymmetric Synthesis of Podophyllotoxin Precursor

(R)‐β‐piperonyl‐γ‐butyrolactones are key building blocks for the synthesis of podophyllotoxin, which have demonstrated remarkable potential in cancer treatment. Baeyer‐Villiger monooxygenases (BVMOs)‐mediated asymmetric oxidation is a green approach to produce chiral lactones. While several BVMOs we...

Full description

Saved in:
Bibliographic Details
Published in:Chembiochem : a European journal of chemical biology 2023-12, Vol.24 (23), p.e202300582-e202300582
Main Authors: Shou‐Cheng Huang, Yi‐Ke Zhang, Geng, Qiang, Qi‐Kang Huang, Jian‐He Xu, Yi‐Feng Chen, Hui‐Lei Yu
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:(R)‐β‐piperonyl‐γ‐butyrolactones are key building blocks for the synthesis of podophyllotoxin, which have demonstrated remarkable potential in cancer treatment. Baeyer‐Villiger monooxygenases (BVMOs)‐mediated asymmetric oxidation is a green approach to produce chiral lactones. While several BVMOs were able to oxidize the corresponding cyclobutanone, most BVMOs gave the (S) enantiomer while Cyclohexanone monooxygenase (CHMO) from Brevibacterium sp. HCU1 gave (R) enantiomer, but with a low enantioselectivity (75 % ee). In this study, we use a strategy called “focused rational iterative site‐specific mutagenesis” (FRISM) at residues ranging from 6 Å from substrate. The mutations by using a restricted set of rationally chosen amino acids allow the formation of a small mutant library. By generating and screening less than 60 variants, we achieved a high ee of 96.8 %. Coupled with the cofactor regeneration system, 9.3 mM substrate was converted completely in a 100‐mL scale reaction. Therefore, our work reveals a promising synthetic method for (R)‐β‐piperonyl‐γ‐butyrolactone with the highest enantioselectivity, and provides a new opportunity for the chem‐enzymatic synthesis of podophyllotoxin.
ISSN:1439-4227
1439-7633
DOI:10.1002/cbic.202300582